Is BSX a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Boston Scientific Corporation (BSX) rests on Farapulse and the Pulsed Field Ablation Wave: The Farapulse pulsed field ablation (PFA) system is the single most important growth driver, helping the electrophysiology business post roughly 37% year-over-year growth in the fourth quarter of 2025. Revenue (TTM) is ~$20.6 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Whether BSX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the fast-growing electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery. Full-year 2025 revenue reached roughly $20 billion, with the Cardiovascular segment delivering about 21-22% organic growth on the strength of Farapulse (which launched in the United States in early 2024) and Watchman. Boston Scientific has built its current profile through both organic innovation and an active acquisition program, and management has guided full-year 2026 organic growth to roughly 6.5% to 8% with adjusted EPS of about $3.34 to $3.41. The investment picture centers on whether the company can keep compounding at high-single to low-double-digit rates as its newest products mature, while defending share against much larger diversified rivals in a market where clinical trial data, physician training, and reimbursement determine winners.
What's the case for buying BSX?
1. Farapulse and the Pulsed Field Ablation Wave
The Farapulse pulsed field ablation (PFA) system is the single most important growth driver, helping the electrophysiology business post roughly 37% year-over-year growth in the fourth quarter of 2025. PFA is reshaping atrial fibrillation treatment by ablating tissue with less collateral damage than older thermal methods, and Boston Scientific was an early leader in the category. The durability of this lead against Medtronic and Johnson and Johnson PFA offerings is the key long-term question.
2. Watchman Franchise Expansion
The Watchman left-atrial-appendage closure device generated roughly $535 million in fourth-quarter 2025 sales, up about 29% year over year, driven by growing adoption of concomitant procedures that combine Watchman with ablation in a single visit. The franchise addresses stroke-risk reduction in atrial fibrillation patients who cannot tolerate long-term blood thinners. Continued clinical evidence and label expansion underpin the growth thesis here.
3. Cardiovascular Leadership and Structural Heart
Beyond electrophysiology, the broader Cardiovascular segment delivered roughly 21% organic growth for full-year 2025, spanning interventional cardiology, peripheral interventions, and structural heart. This breadth gives Boston Scientific multiple procedure-volume tailwinds tied to an aging global population and the ongoing shift toward minimally invasive treatment. Recent and pending product approvals broaden the addressable patient base.
4. MedSurg Diversification
The MedSurg segment, covering endoscopy, urology, and neuromodulation, provides steadier mid-single-digit growth that diversifies the company away from pure cardiovascular exposure. While it grows more slowly than Cardiovascular, it contributes meaningful recurring revenue and cross-selling into the same hospital customer base. Management continues to invest in and occasionally acquire adjacent technologies to strengthen these franchises.
What are the risks to BSX?
The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could erode Boston Scientific's early PFA share and pressure pricing. The stock has historically carried a premium valuation, so any slowdown in the growth narrative can trigger outsized share-price reactions, as seen in a sharp post-earnings selloff. Foreign exchange swings, hospital capital-spending cycles, product-recall or safety-signal risk inherent to implantable devices, and reimbursement or regulatory changes each add uncertainty. Integration risk from the company's ongoing acquisition strategy is a further variable that can affect margins and management focus.
How is BSX valued? (as of July 2026)
Snapshot for BSX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$20.6 billion
- Revenue (FY 2025): ~$20 billion
- Q1 2026 Revenue: ~$5.2 billion (+11.6% YoY reported, ~9.4% organic)
- Adjusted EPS Guidance (FY 2026): ~$3.34 to $3.41 (9% to 11% growth)
- Market Cap: ~$65 billion
- P/E Ratio (trailing): ~18x (forward ~13x)
Boston Scientific's trailing P/E of roughly 18x sits well below the peer-group average of roughly 34x cited by valuation trackers, a reversal from the sustained premium multiple the stock carried during its high-growth phase. The compression followed a steep share-price decline over the trailing year that coincided with a downward revision to organic growth guidance and disappointing signals in electrophysiology, Watchman, and urology. Net profit margin runs near 17%, and full-year 2026 adjusted EPS growth is guided to 9% to 11%, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction relative to the franchise's still-double-digit earnings trajectory.
How do you decide if BSX is a buy?
Rather than asking whether BSX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BSX indirectly through an index or sector ETF before adding more.
For the full picture, see the BSX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BSX against your real portfolio and see your actual exposure before deciding.
The bottom line on BSX
The bottom line: Boston Scientific Corporation's story right now is Farapulse and the Pulsed Field Ablation Wave, with revenue (ttm) at ~$20.6 billion. If you believe that narrative continues, the call is about sizing BSX sensibly and checking overlap with what you own; if you doubt it (the risk: the most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around BSX with Walnut
Use Boston Scientific Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BSX a good stock to buy right now?
+
The case for Boston Scientific Corporation right now is Farapulse and the Pulsed Field Ablation Wave, with revenue (ttm) at ~$20.6 billion. If you believe that thesis holds, BSX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Boston Scientific Corporation do?
+
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventiona
What are the main risks of BSX?
+
The most immediate concern flagged with 2026 guidance was unanticipated headwinds in electrophysiology, Watchman, and urology, which prompted management to frame organic growth guidance of 6.5% to 8%, below the pace of recent years and a signal that the newest franchises may be decelerating from peak growth rates. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could erode Boston Scientific's early PFA share and pressure pricing. The stock has historically carried a premium valuation, so any slowdown in the growth narrative can trigger outsized share-price reactions, as seen in a sharp post-earnings selloff. Foreign exchange swings, hospital capital-spending cycles, product-recall or safety-signal risk inherent to implantable devices, and reimbursement or regulatory changes each add uncertainty. Integration risk from the company's ongoing acquisition strategy is a further variable that can affect margins and management focus.
What does Boston Scientific do?
+
Boston Scientific develops and sells minimally invasive medical devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, and neuromodulation. It reports through two segments, Cardiovascular and MedSurg, and sells to hospitals and physicians in roughly 130 countries. Its highest-profile products include the Farapulse pulsed field ablation system and the Watchman heart-implant device.
Is BSX a good stock to invest in right now?
+
That depends on your horizon and risk tolerance. Boston Scientific is still growing earnings at a guided 9% to 11% for 2026 and trades at roughly 18x trailing earnings, well below its historical premium after a sharp share-price decline. However, management flagged decelerating growth in electrophysiology, Watchman, and urology, and competition in pulsed field ablation is intensifying. Investors weigh those trade-offs differently.
Does Boston Scientific pay a dividend?
+
Boston Scientific has historically reinvested cash into research, development, and acquisitions rather than paying a regular dividend, positioning itself as a growth-oriented medical device company. Investors in BSX have generally sought total return from share-price appreciation rather than income. Always confirm the current dividend policy with your broker or the company's investor relations page before investing.
Who are Boston Scientific's main competitors?
+
Its principal rivals are Medtronic and Johnson and Johnson in electrophysiology and cardiac devices, Abbott across cardiac rhythm management, electrophysiology, and structural heart, and Edwards Lifesciences in structural heart valves. In its MedSurg segment it competes with Stryker, Olympus, and others in endoscopy, urology, and neuromodulation. No single competitor overlaps across all of Boston Scientific's franchises.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell BSX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.